以表皮生長因子受體酪氨酸激酶抑制劑（EGFR-TKI）為代表的分子靶向藥物治療腫瘤，可明顯延長非小細(xì)胞肺癌患者的無進(jìn)展生存期和改善患者的生活質(zhì)量，但面臨耐藥以及耐藥后如何繼續(xù)治療等問題。闡述EGFR-TKI的作用機(jī)制和獲得性耐藥機(jī)制，分別對耐藥后快速進(jìn)展、緩慢進(jìn)展和局部進(jìn)展3種進(jìn)展情況提出了診療意見，以期為改善耐藥、加強(qiáng)療效提供借鑒。

On the behalf of molecule targeted drugs, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) can prolong the progression free survival and improve life quality of non-small-cell lung cancer patients, yet the drug-resisitance and treatment after can not be ignored. State the mechanism of EGFR-TKI and acquired drug-resistance, provide treatment opinions for rapid progress, slow progress and local advancement, meanwhile achieving the target of reversing drug-resistance and strengthening curative effect.

天津市高等學(xué)?？萍及l(fā)展基金計劃項目（20110223）